Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Bortezomib + Daratumumab + Dexamethasone + Thalidomide |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Bortezomib | Velcade | Velcade (bortezomib) is a reversible proteasome inhibitor that inhibits survival of malignant cells and regulates bone remodeling (PMID: 26579531). Velcade (bortezomib) is FDA approved for the treatment of mantle cell lymphoma and multiple myeloma (FDA.gov). | ||
Daratumumab | Darzalex | JNJ-54767414 | CD38 Antibody 20 | Darzalex (Daratumumab) is a human antibody against CD38 that induces antibody-dependent cell-mediated cytotoxicity and complement-mediated cytotoxicity against CD38-positive tumor cells (PMID: 30546360). Darzalex (Daratumumab) is FDA approved for multiple myeloma patients as a monotherapy or in combination with lenalidomide and dexamethasone, or with bortezomib and dexamethasone, or with bortezomib, melphalan, and prednisone, or with pomalidomide and dexamethasone, or with bortezomib, thalidomide and dexamethasone (FDA.gov). |
Dexamethasone | Adexone | Desametasone | ||
Thalidomide | Thalomid | N-Phthalimidoglutamic acid imide | Thalomid (thalidomide) is a a racaemic glutamic acid analogue that has anti-inflammatory, anti-angiogenic, immunosuppressive, and anti-tumor activities (PMID: 15172781). Thalomid (thalidomide) is approved for use in combination with dexamethasone for patients with newly diagnosed multiple myeloma (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04352205 | Phase II | Bortezomib + Daratumumab + Dexamethasone + Lenalidomide Bortezomib + Daratumumab + Dexamethasone + Thalidomide | Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure | Terminated | USA | 0 |